The Biological Activity of Nonsteroidal Vitamin D Hormone Analogs Lacking Both the C- and D-Rings
Open Access
- 1 April 1998
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of Bone and Mineral Research
- Vol. 13 (4) , 549-558
- https://doi.org/10.1359/jbmr.1998.13.4.549
Abstract
1α,25-dihydroxyvitamin D is a key calcium-regulating hormone but also displays potent differentiating and antiproliferative activities on many cell types. The structural requirements of this secosteroid hormone have been extensively studied for the A-ring and side chain, whereas relatively little is known about the requirements of the natural CD-ring structure for the vitamin D–like biological activity. We have embarked on a vast program in which derivatives were synthesized and evaluated characterized by profound structural changes in the central C/D-region. This first series of nonsteroidal analogs consists of (1R,3S)-5-((Z,2E)-4-((1S,3S)-3-(4-hydroxy-4-methylpentyl)-1,2,2,-trimethylcyclopentyl)-2-butenylidene)-4-methylenecyclohexane-1,3-diol (KS 176) and derivatives thereof. These analogs are characterized by the absence of normal C- and D-rings and by the presence of an unnatural five-membered ring which we call the E-ring. KS 176 with the otherwise natural side chain structure of 1α,25(OH)2D3 has between 10 and 30% of the biological activity of 1α,25(OH)2D3 when tested in vitro (prodifferentiating effects on HL-60 and MG-63; antiproliferating activity on MCF-7 and keratinocytes) but has minimal in vivo calcemic effects. Introduction of several side chain modifications created analogs with increased intrinsic noncalcemic biological properties, whereas their calcemic potency remains very low. These data demonstrate that the full CD-rings are not mandatory for the biological activity of 1α,25(OH)2D3 since they can be replaced by a new ring structure which generates an appropriate spacing of the A-seco B-rings in relation to the side chain. The biological activity of these nonsteroidal analogs probably involves a classical genomic activation since they are also active in transfection assays using an osteocalcin vitamin D responsive element coupled to a human growth hormone reporter gene.Keywords
This publication has 45 references indexed in Scilit:
- 1α,25(OH)2Vitamin D3-Regulated Expression of the Eukaryotic GenomeNutrition Reviews, 2009
- Synthesis of CD-ring modified 1α,25-dihydroxy vitamin D analogues : E-ring analoguesBioorganic & Medicinal Chemistry Letters, 1996
- Non-hypercalcemic pharmacological aspects of vitamin D analogsBiochemical Pharmacology, 1995
- 1β, 25(OH)2-vitamin D3 is an antagonist of 1α,25(OH)2-vitamin D3 stimulated transcaltachia (The rapid hormonal stimulation of intestinal calcium transport)Biochemical and Biophysical Research Communications, 1992
- Aromatase and its inhibitors—an overviewThe Journal of Steroid Biochemistry and Molecular Biology, 1991
- A chemical classification of nonsteroidal antagonists of sex-steroid hormone actionJournal of Steroid Biochemistry, 1988
- Synthetic analogues of vitamin D3 with an oxygen atom in the side chain skeleton A trial of the development of vitamin D compounds which exhibit potent differentiation‐inducing activity without inducing hypercalcemiaFEBS Letters, 1987
- 1,25-Dihydroxyvitamin D3-induced differentiation in a human promyelocytic leukemia cell line (HL-60): receptor-mediated maturation to macrophage-like cells.The Journal of cell biology, 1984
- Comparative study of the affinity of the serum vitamin d-binding proteinThe Journal of Steroid Biochemistry and Molecular Biology, 1980
- A proton magnetic resonance nuclear Overhauser enhancement study. Application to vitamin D derivatives D2 and D3Canadian Journal of Chemistry, 1980